Analysts who follow Relmada Therapeutics Inc (RLMD) on average expect it to gain 528.85% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns the stock an Analyst Ranking of 20, which means it ranks higher than 20 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating RLMD a Buy today. Find out what this means to you and get the rest of the rankings on RLMD!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Relmada Therapeutics Inc Stock Today?
Relmada Therapeutics Inc (RLMD) stock is higher by 10.07% while the S&P 500 has fallen -0.61% as of 12:56 PM on Thursday, Aug 24. RLMD is up $0.29 from the previous closing price of $2.93 on volume of 115,704 shares. Over the past year the S&P 500 is up 6.48% while RLMD has fallen -89.99%. RLMD lost -$4.29 per share the over the last 12 months.
Click Here to get the full Stock Report for Relmada Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
